Proton pump inhibitors: Compliance with a mandated step-up program

Canadian Family Physician

Volumn 47, Issue MAR., 2001, Pages 531-535

  Mamdani, Muhammad M ^b   Tu, Karen ^c   Jaakkimainen, Liisa ^c   Bica, Adina ^c   Hux, Janet ^a  

^a ONTARIO MINISTRY OF HEALTH AND LONG TERM CARE   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; NIZATIDINE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE;

ARTICLE; CANADA; CLINICAL PRACTICE; DRUG COST; DRUG UTILIZATION; GASTRITIS; GASTROESOPHAGEAL REFLUX; HUMAN; MENTAL COMPLIANCE; PRACTICE GUIDELINE; PRESCRIPTION;

AGED; ANTI-ULCER AGENTS; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; DYSPEPSIA; FAMILY PRACTICE; FEMALE; GASTROENTEROLOGY; GUIDELINE ADHERENCE; H(+)-K(+)-EXCHANGING ATPASE; HEALTH POLICY; HISTAMINE H2 ANTAGONISTS; HUMANS; INTERNAL MEDICINE; LOGISTIC MODELS; MALE; NATIONAL HEALTH PROGRAMS; ONTARIO; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PROTON PUMPS; RETROSPECTIVE STUDIES;

EID: 0035057660     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Talley NJ, O'Keefe EA, Zinsmeister AR, Melton LJ. Prevalence of gastrointestinal symptoms in the elderly: a population-based study. Gastroenterology 1992;102(3):895-901.
2. Bateman DN. Proton-pump inhibitors: three of a kind? Lancet 1997;349:1637-8.
3. Roberts SJ, Bateman DN. Prescribing of antacids and ulcer-healing drugs in primary care in the north of England. Aliment Pharmacol Ther 1995;9(2):137-43.
4. Walan A, Eriksson S. Long-term consequences with regard to clinical outcome and cost-effectiveness of episodic treatment with omeprazole or ranitidine for healing of duodenal ulcer. Scand J Gastroenterol Suppl 1994;210(Suppl):91-7.
5. Harris RA, Kuppermann M, Richter JE. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis. Am J Gatroenterol 1997;92(12):2179-87.
6. Hillman AL. Economic analysis of alternative treatments for persistent gastrooesophageal reflux disease. Scand J Gastroenterol Suppl 1994;201(Suppl):98-102.
7. Bashfrod JNR, Norwood J, Chapman SR. Why are patients prescribed proton pump inhibitors? Retrospective analysis of the link between morbidity and prescribing in the General Research Database. BMJ 1998;317:452-6.
8. Bardhan KD, Muller-Lissner S, Bigard MA, Porro GB, Ponce J, Hosie J, et al. Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. BMJ 1999;318:502-7.
9. Eggleston A, Wigerinck A, Huijghebaert S, Dubois D, Haycox A. Cost effectiveness of treatment for gastro-oesophageal reflux disease in clinical practice: a clinical database analysis. Gut 1998;42:13-6.
10. Beck IT, Champion MC, Lemire S, Thomson AB, Anvari M, Armstrong D, et al. The Second Canadian Consensus Conference on the Management of Patients with Gastroesophageal Reflux Disease. Can J Gastroenterol 1997;11(Suppl B):7-20B.
11. McBride JE, Pater JL, Dorland JL, Lam Y-M. Extent and variation of omeprazole prescribing in an elderly population of Ontario. Ann Pharmacother 1997;31:411-6.
12. McManus P, Marley J, Birkett DJ, Lindner J. Compliance with restrictions on the subsidized use of proton pump inhibitors in Australia. Br J Clin Pharmacol 1998;46(4):409-11.
13. World Health Organization Collaborating Centre for Drug Statistics Methodology. ATC index with DDDs. Geneva, Switz: World Health Organization; 1999.
14. Kudenchuk PJ, Maynard C, Martin JS, Wirkus M, Weaver WD. Comparison of presentation, treatment, and outcome of acute myocardial infarction in men versus women (the Myocardial Infarction Triage and Intervention Registry). Am J Cardiol 1996;78(1):9-14.